Biotech

Companies & Industries News

Biotech Companies & Industries Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 17.11.2021.

#NBThighlight
#RoseTTAFold
#AlphaFold
#migraine
#pharma

Companies And Industries

@NatureBiotech shared
On Nov 16, 2021
Deep learning predicts the structure of protein complexes based on paired multiple sequence alignments and amino acid coevolution analysis. #NBThighlight https://t.co/PzKkSH4hQp
Open
Computed structures of core eukaryotic protein complexes

Computed structures of core eukaryotic protein complexes

We take advantage of advances in proteome-wide amino acid coevolution analysis and deep-learning-based structure modeling to systematically identify and build accurate models of …

@SENGLAITAN shared
On Nov 17, 2021
Sensitive identification of neoantigens and cognate TCRs in human solid tumors https://t.co/JFZWFvykhT
Open
Sensitive identification of neoantigens and cognate TCRs in human solid tumors

Sensitive identification of neoantigens and cognate TCRs in human solid tumors

NeoScreen helps identify rare tumor antigens for personalized cancer vaccines and T cell therapies.

@biospace shared
On Nov 11, 2021
Biotech companies are expanding the frontiers of engineered cell therapy https://t.co/bu9e9xOFvY
Open
Biotech Companies are Expanding the Frontiers of Engineered Cell Therapy

Biotech Companies are Expanding the Frontiers of Engineered Cell Therapy

Celares and Mission Bio are part of the rapidly evolving push to create and characterize the superhuman powers cells can be endowed with. 

@FierceBiotech shared
On Nov 16, 2021
Like other molecules before it, ensovibep failed a planned futility analysis, leading to a recommendation to stop enrollment in the sub-study. Shares in Molecular Partners fell 37% in Switzerland https://t.co/3dGQn0o7Uu
Open
Novartis-partnered DARPin flames out in COVID-19 study, sending Molecular Partners' stock into nosedive

Novartis-partnered DARPin flames out in COVID-19 study, sending Molecular Partners' stock into nosedive

ACTIV-3 has claimed yet another victim. Molecular Partners and Novartis are the latest companies to fail to clear the efficacy bar in the NIH-sponsored COVID-19 study, leaving their hopes ...

@pharmaphorum shared
On Nov 15, 2021
As its Vyepti #migraine therapy starts to gather momentum, Danish #pharma company @Lundbeck starts mid-stage trials of a new-mechanism drug that could extend its franchise https://t.co/RI3nZbbtQC
Open
Amid crowded migraine market, Lundbeck goes its own way

Amid crowded migraine market, Lundbeck goes its own way

As its Vyepti migraine therapy starts to gather momentum, Danish pharma company Lundbeck starts mid-stage trials of a new-mechanism drug that could extend its franchise

@matthewherper shared
On Nov 11, 2021
RT @RebeccaDRobbins: It was such a pleasure returning to @statnews' podcast this morning to talk about the NIH-Moderna patent dispute. Thanks for having me on the show, @adamfeuerstein @megtirrell @damiangarde @sayhitohyacinth @_gaffknee https://t.co/yc4HeULmdF
Open
Listen: Moderna v. NIH, psilocybin as a medicine, & the cultural intake of pharma CEOs

Listen: Moderna v. NIH, psilocybin as a medicine, & the cultural intake of pharma CEOs

Rebecca Robbins of the New York Times joins us to discuss the escalating tension between Moderna and the NIH over a Covid-19 vaccine.

@ScienceNews shared
On Nov 16, 2021
Humans have meddled with nature for 50,000 years. There's no backing out now. https://t.co/HVwzCJPYDT
Open
‘Life as We Made It’ charts the past and future of genetic tinkering

‘Life as We Made It’ charts the past and future of genetic tinkering

A new book shatters illusions that human meddling with nature has only just begun.

@GENbio shared
On Nov 11, 2021
This eBook explores timely topics in the diagnostics landscape, from regulatory considerations and next-generation COVID-19 diagnostics to an innovative next-generation sequencing initiative. Read more: https://t.co/u539KWTJAO https://t.co/QRaaxdgoFz
Open
Advancements in Precision Diagnostics: New Regulations and Biomarker Strategies

Advancements in Precision Diagnostics: New Regulations and Biomarker Strategies

In this eBook, we explore timely topics in the diagnostics landscape, from regulatory considerations and next-generation COVID-19 diagnostics to an innovative next-generation sequencing ...